Companion Diagnostics

News on companion diagnostics and drug/test co-development.

Sep 9, 2022

Roche Obtains CE Mark for Ventana PD-L1 Assay as CDx for Libtayo

Sep 8, 2022

OncXerna Begins Navicixizumab Phase II Basket Trial

Aug 26, 2022

Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan

Aug 24, 2022

Myriad Genetics, Clarified Precision Medicine Team up on Molecular Tumor Board Service

Aug 22, 2022

Pillar Biosciences Receives China Approval for Colon Cancer Companion Diagnostic Assay

Aug 16, 2022

Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug

Aug 11, 2022

Roche Nabs FDA Label Expansion for Ventana CDx Panel

Aug 9, 2022

Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics

Jul 15, 2022

Almac, AstraZeneca CDx Partnership Branching Out to New Disease Areas, Drawing on NGS, qPCR
Premium

Jul 11, 2022

HER2-Low Response Data Spurs Paige to Develop New Breast Cancer Pathology Test
Premium

Jun 28, 2022

Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx

Jun 22, 2022

Acrivon Therapeutics to Study CHK1/2 Inhibitor ACR-368, Predictive Diagnostic in Phase II Trial

Jun 22, 2022

Biocartis, AstraZeneca Ink Companion Diagnostic Pact

Jun 13, 2022

OncoHost Licenses SomaLogic Platform to Develop Tests to Predict Patient Response to Immunotherapies

Jun 9, 2022

FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek

Jun 6, 2022

Foundation Medicine, Arvinas Partner to Develop CDx For Prostate Cancer Drug

Jun 2, 2022

Grail, AstraZeneca Partner on Companion Dx for Oncology Drugs

May 10, 2022

Agilent Obtains CE-IVD Mark for CDx to ID Cervical Cancer Patients Suitable for Keytruda

May 4, 2022

NGeneBio Receives CE-IVD Mark for NGS-Based Cancer Panel

Apr 27, 2022

Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines